Clinical Efficacy of Actovegin in Complex Treatment of Patients with Diabetes Mellitus Type 2 with Diabetic Polyneuropathy Against Arterial Hypertension
Main Article Content
Abstract
The aim of the study — to evaluate the clinical efficacy of Actovegin in complex treatment of patients with diabetes mellitus (DM) type 2 diabetic polyneuropathy (DPN) with arterial hypertension (AH). We observed 53 patients with DM type 2 with DPN against AH, who served as controls (n = 25) and study
(n = 28) group. Patients of study group in addition to the basic therapy received intravenous infusions of 400 mg of Actovegin for 10 days. It is found that the use of Actovegin in comprehensive treatment of DM type 2 with DPN against AH improves the clinical picture of the disease, which is associated with reduction in intensity of thirst, dry mouth, weakness, rapid fatigability, headache and dizziness, normalization of blood pressure. Actovegin has a positive effect on symptoms of DPN, resulting an increase in all kinds of sensitivity, decrease in degree of pain syndrome. Administration of Actovegin in the treatment of DM type 2 improves the glycemic profile, reduces the level of peripheral insulin resistance, and also has a beneficial potentiating action on the abnormal lipid metabolism.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
References
Law D.W. The worldwide diabetes epidemic / D.W. Law, D. LeRoith // Curr. Opin. Endocrinol. Diabetes Obes. — 2012. — Vol. 19, № 2. — P. 93-96.
Кисляк О.А. Сахарный диабет 2 типа, артериальная гипертензия и риск сердечно-сосудистых осложнений / О.А. Кисляк, Т.О. Мышляева, Н.В. Малышева // Сахарный диабет. — 2008. — № 1(38). — С. 45-49.
Ndip A. Neuropathic diabetic foot ulcers — evidence-to-practice / A. Ndip, L. Ebah, A. Mbako // Int. J. Gen. Med. — 2012. — Vol. 5. — P. 129-134.
Won J.C. Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea / J.C. Won, H.S. Kwon, C.H. Kim [et al.] // Diabet. Med. — 2012. — Vol. 29, № 9. — P. 290-296.
Dieckmann A. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation / A. Dieckmann, M. Kriebel, E. Andriambeloson [et al.] // Exp. Clin. Endocrinol. Diabetes. — 2012. — Vol. 120, № 3. — P. 132-138.